Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 6/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.60 |
| ▸ | PKM | P14618 | 3/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 4/20 | 0.56 |
| ▸ | MAPT | P10636 | 7/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.54 |
| ▸ | RELA | Q04206 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | ABCG2 | Q9UNQ0 | 4/20 | 0.53 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6792926 | 0.89 | MEN1 (0.54) | JAK2MEN1KMT2AL3MBTL1MAPK1 | |
| SCHEMBL31157922 | 0.87 | MEN1 (0.54) | JAK2MEN1KMT2AL3MBTL1MAPK1 | |
| SCHEMBL6799661 | 0.86 | ABCG2 (0.52) | JAK2MEN1KMT2AL3MBTL1MAPK1 | |
| SCHEMBL2781396 | 0.85 | NPC1 (0.67) | MEN1KMT2AL3MBTL1MAPK1PKM | |
| SCHEMBL13730771 | 0.84 | MAPT (0.50) | JAK2MEN1KMT2AL3MBTL1MAPK1 | |
| SCHEMBL6797348 | 0.83 | MAPT (0.54) | JAK2MEN1KMT2AL3MBTL1MAPK1 | |
| SCHEMBL6796759 | 0.83 | MAPT (0.56) | MEN1KMT2AL3MBTL1MAPK1NPC1 | |
| SCHEMBL7830242 | 0.81 | MAPT (0.61) | MEN1KMT2AL3MBTL1MAPK1PKM | |
| SCHEMBL6799279 | 0.81 | MAPT (0.58) | MEN1KMT2AL3MBTL1MAPK1PKM | |
| SCHEMBL27362918 | 0.80 | MAPT (0.56) | JAK2MEN1KMT2AL3MBTL1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6727245-B2 | 4-(HETERO)ARYL-3-OXO-3,4-DIHYDROPYRIDO(2,3-B)PYRAZINE DERIVATIVES; PROPHYLACTIC OR THERAPEUTIC TREATMENT OF PHOSPHODIESTERASE IV AND TUMOR NECROSIS FACTOR MEDIATED DISEASES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-04-27 | — | — | US | disclosed |
| EP-0770079-B1 | HETEROBICYCLIC DERIVATIVES | FUJISAWA PHARMACEUTICAL CO (JP) | 2003-02-12 | — | — | EP | disclosed |
| US-20020107251-A1 | Heterobicyclic derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-08-08 | — | — | US | disclosed |
| US-6426345-B1 | PHOSPHODIESTERASE INHIBITORS; ANTIINFLAMMATORY AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-07-30 | — | — | US | disclosed |
| EP-0920867-A1 | Pyrido[2,3-a]pyrazine derivatives as PDE-IV and TNF inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-06-09 | — | — | EP | disclosed |
| EP-0770079-A1 | HETEROBICYCLIC DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-05-02 | — | — | EP | disclosed |
| WO-1996001825-A1 | HETEROBICYCLIC DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-01-25 | — | — | WO | disclosed |
| US-4698430-A | ANTIDEPRESSANT | A. H. ROBINS COMPANY, INC. (US) | 1987-10-06 | — | — | US | disclosed |
| US-4558132-A | ANTIDEPRESSANTS | A. H. ROBINS COMPANY, INCORPORATED (US) | 1985-12-10 | — | — | US | disclosed |
| EP-0099614-A2 | Nitro, amino and aroylamino-N-phenylpyridinamines and their use in a process for preparing pyrido(1,4)benzodiazapines | A.H. ROBINS COMPANY, INCORPORATED (US) | 1984-02-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107251-A1 | Heterobicyclic derivatives | ARSA, ARRB1, SULT2A1 | JAK2 891/4885MEN1 2703/4885KMT2A 968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.